Soleno Therapeutics (SLNO)
(Real Time Quote from BATS)
$48.11 USD
+1.23 (2.62%)
Updated Sep 25, 2024 11:00 AM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Price, Consensus and EPS Surprise
SLNO 48.11 +1.23(2.62%)
Will SLNO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SLNO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SLNO
Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review
Soleno Therapeutics, Inc. (SLNO) Is a Great Choice for 'Trend' Investors, Here's Why
SLNO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Momentum in Soleno Therapeutics, Inc. (SLNO) Should Keep going
Here's What Could Help Soleno Therapeutics, Inc. (SLNO) Maintain Its Recent Price Strength
Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study Data
Other News for SLNO
Nantahala Capital Management Reduces Stake in America's Car-Mart Inc
Nantahala Capital Management's Recent Transaction in Evoke Pharma Inc
Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference
Carlyle Group Inc.'s Strategic Reduction in Soleno Therapeutics Inc.
Soleno Therapeutics initiated with bullish view at H.C. Wainwright, here's why